363 related articles for article (PubMed ID: 29243219)
1. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.
Wang CY; Hua R; Liu L; Zhan X; Chen S; Quan S; Chu QJ; Zhu YT
Cancer Med; 2017 Mar; 6(3):689-697. PubMed ID: 28205361
[TBL] [Abstract][Full Text] [Related]
4. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
5. The granulocyte macrophage-colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer.
Zhu YT; Zhao Z; Fu XY; Luo Y; Lei CY; Chen W; Li F; Pang SY; Chen SS; Tan WL
Stem Cell Res; 2014 Jul; 13(1):111-22. PubMed ID: 24874290
[TBL] [Abstract][Full Text] [Related]
6. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
7. Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine.
Zhu YT; Pang SY; Lei CY; Luo Y; Chu QJ; Tan WL
Stem Cell Res Ther; 2015 Nov; 6():224. PubMed ID: 26566931
[TBL] [Abstract][Full Text] [Related]
8. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
10. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer.
Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W
Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375
[TBL] [Abstract][Full Text] [Related]
12. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
13. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
14. Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
Miyake M; Hori S; Ohnishi S; Toritsuka M; Fujii T; Shimizu T; Owari T; Morizawa Y; Gotoh D; Itami Y; Nakai Y; Anai S; Torimoto K; Tanaka N; Fujimoto K
Cancer Sci; 2019 Oct; 110(10):3315-3327. PubMed ID: 31385407
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.
Karyampudi L; Lamichhane P; Scheid AD; Kalli KR; Shreeder B; Krempski JW; Behrens MD; Knutson KL
Cancer Res; 2014 Jun; 74(11):2974-85. PubMed ID: 24728077
[TBL] [Abstract][Full Text] [Related]
16. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
18. A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer.
Yin W; He Q; Hu Z; Chen Z; Qifeng M; Zhichun S; Zhihui Q; Xiaoxia N; Li J; Gao J
Vaccine; 2010 Jul; 28(31):4937-44. PubMed ID: 20653081
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
20. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
